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Introduction {#sec005}
============

Visceral leishmaniasis (VL) or kala-azar is the severest form of leishmaniasis and fatal if left untreated. More than 90% of global VL cases occur in just six countries: India, Bangladesh, Sudan, South Sudan, Brazil and Ethiopia \[[@pntd.0007216.ref001]\]. India accounts for approximately 50% of the global burden of VL and is a signatory to a Tripartite Memorandum of Understanding (MoU) to achieve VL elimination from the South-East Asia Region (SEAR). The goal is to reduce the annual incidence of VL to less than 1 case per 10,000 population at the sub-district (*block*) level \[[@pntd.0007216.ref002], [@pntd.0007216.ref003]\]. This elimination target is expressed as a number of new clinical cases of VL per person-year. However, it is established that many *L*. *donovani* infections do not lead to a clinical episode of VL and that asymptomatic infections far outnumber the clinical cases \[[@pntd.0007216.ref004]\]. A prospective study in India and Nepal showed a ratio of incident asymptomatic infection, measured by recent conversion in antibody tests, to clinical disease of 9 to 1 while in neighboring Bangladesh it was 4 to 1 \[[@pntd.0007216.ref005], [@pntd.0007216.ref006]\]. Mathematical modeling has suggested that transmission of *L*.*donovani* could be maintained by asymptomatically infected hosts \[[@pntd.0007216.ref007], [@pntd.0007216.ref008]\]. Therefore the study of asymptomatic infection is considered a key research priority to support the VL elimination initiative \[[@pntd.0007216.ref009]\]. Currently, xenodiagnosis studies are ongoing in India and Bangladesh to establish whether asymptomatic carriers of *L*.*donovani* infection are infectious to sand flies, but there are other issues to address as well.

Mathematical modeling has suggested that detecting and treating clinical cases early enough is key to reducing their transmission potential \[[@pntd.0007216.ref010], [@pntd.0007216.ref011]\] and therefore, it would be useful if one could identify the infected persons who are most likely to progress to clinical disease. To date it is not established which are the best predictors for the development of active VL disease in somebody with a positive leishmanial infection marker but no signs and symptoms. A strong association has been observed between high baseline antibody titers and progression to VL in the subsequent 36 months in large cohort studies in India, Nepal and Bangladesh \[[@pntd.0007216.ref012], [@pntd.0007216.ref013]\]. In the above mentioned studies in India and Nepal, even stronger associations for progression to VL were observed with recent seroconversion to high antibody titers.

Whether an infection remains asymptomatic or progresses towards VL probably results from the complex interaction between genetic susceptibility and immune response of the host, combined with parasite, socioeconomic and demographic factors. A genome-wide association study (GWAS) carried out in India showed that HLA class II alleles, in particular, HLA-DRB1, are major genetic risk factors for VL. Sequence-based classical HLA typing and haplotype analysis suggest that risk allele(s) in India belong to HLA-DRB1\*13/\*14 allele groups and protective alleles to HLA-DRB1\*15 allele group \[[@pntd.0007216.ref014]\]. However, the relative contribution of these different factors to the development of VL is still not well understood. We assessed immunological and genetic markers for progression to active clinical disease in a large prospective cohort study in Bihar, India. Our aim was to identify markers that are predictors of progression from *L*.*donovani* infection to clinically symptomatic VL.

Methods {#sec006}
=======

We conducted this prospective study in two high VL incidence areas of Muzaffarpur district, Bihar State, India from 2008--2015.

Ethical considerations {#sec007}
----------------------

The review committee of the U.S. National Institutes of Health (NIH), as well as the Institutional Review Boards of the Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, Institute of Tropical Medicine, Belgium and the University of Iowa reviewed the study protocol and gave ethical clearance for this study. Data was anonymized. All subjects provided written informed consent; in case of illiterate subjects, a thumb print plus a signature of an independent witness was obtained. For minors under the age of 18 years, informed consent was obtained from a parent or guardian.

Study population {#sec008}
----------------

The study was conducted in two areas. The first area (Area-1) had a total population of 19,634 divided over 11 villages with high VL incidence rates before 2009. Two house to house surveys were conducted in Area-1at a one-year interval between December 2009 and February 2011. All residents above two years of age who were present and gave their informed consent (or whose parents gave consent, for minors) were enrolled in the study. A capillary blood sample was obtained on pre-printed Whatmann filter paper in consenting participants and rK39-ELISA, and DAT tests were performed to detect antibodies against VL. Those individuals testing negative for both the tests in the first sero-surveywere re-tested in the second serosurvey in the following year. We defined seroconverters as subjects negative on rK39-ELISA and DAT in the first sero-survey but positive on either of the two assays during the second survey. For each seroconverter a control who was rK39-ELISA and DAT-negative on both survey rounds was recruited into the study, controls were group matched according to age (\<10, 10--18 or \>18 years) and village of residence.

An interim analysis in 2010 showed that, due to a declining incidence trend of VL, the target sample size of 600 seroconverters could not be achieved \[[@pntd.0007216.ref012]\]. Therefore we selected an additional study area (Area 2) of 10,729 population living in 1,836 households in 16 geographically scattered villages. Villages were selected based on reported recent high VL incidence levels. In this area two similar serosurveys were conducted six months apart to recruit more seroconverters. This time we recruited four controls for each seroconverter, based on the same matching criteria \[[@pntd.0007216.ref012], [@pntd.0007216.ref015]\].

Study procedures {#sec009}
----------------

All seroconverters and their controls were interviewed to gather baseline demographic and medical history data, and were clinically examined. At the time of recruitment 5 ml of blood was obtained from seroconverters and controls for the following tests: DAT, rK39-ELISA, Quantiferon assay (IFN-γ release assay), SNP/HLA genotyping and quantitative PCR (qPCR). Both the seroconverters and controls were followed up monthly for the development of clinical symptoms of VL. In case of clinical suspicion (i.e. more than 2 week fever history and rK39 RDT positivity), VL was confirmed parasitologically by splenic smear and treated with Amphotericin B as per national guideline recommendation \[[@pntd.0007216.ref016]\]. All the participants were followed up for a minimum of 3 years.

Laboratory tests {#sec010}
----------------

### Direct agglutination test (DAT) {#sec011}

The standard procedure was followed as described elsewhere \[[@pntd.0007216.ref017]\]. Briefly 100 μl of 1:400 diluted serum samples were serially diluted up to 1:51,200 in V-shaped, microtitre plates in DAT diluents with one positive and one negative control run every fifth plate. Wells in the last row were kept for antigen control. 50 μl of DAT antigen was dispensed to every well \[[@pntd.0007216.ref018]\]. Plates were covered, shaken gently and incubated overnight at room temperature. The DAT results were read against a white background and samples with a titer ≥1:1600 were considered positive.

### rK39-ELISA {#sec012}

rK39-ELISA was performed as described elsewhere \[[@pntd.0007216.ref019]\]. The optical density (OD) measurements were undertaken at 450nm using a microtitre plate ELISA reader (Molecular Devices, USA). A positive (parasitologically confirmed VL case) and a negative control (filter paper eluate from non-endemic healthy control, NEHC) were run in each plate and the positive control was used as a reference to calculate a relative value of positivity of each sample. Results were expressed as the subject's optical density (OD) value divided by the OD value of a positive control serum sample ×100, and called percentage point positivity (pp) of a positive control. PP was log transformed to compensate for skewed distribution. The resulting standard value 14 percent of the OD of a positive control was considered for deciding the positivity of samples (cut-off decided for Indian population) \[[@pntd.0007216.ref012]\].

### IFN-γ release assay (IGRA) {#sec013}

A whole blood assay for detection of antigen-specific IFN-γ production in vitro, and its use in identifying asymptomatically infected individuals in Bihar, has been described \[[@pntd.0007216.ref020], [@pntd.0007216.ref021]\]. Briefly, 3 ml heparinized whole blood was dispensed in tubes as 1 ml each and incubated PBS, SLA and positive control (phytohemagglutinin, PHA). After 20--24 hr incubation at 37°C, the supernatant (approx 400 μl) were collected from each well and stored for measurement of IFN-γ concentration by ELISA. Antigen-specific IFN-γ levels (expressed as IU/ml) produced in response to SLA stimulation were determined by subtracting background levels measured in the non-stimulated (NIL, PBS) samples. The result was considered positive when the IFN-γ concentration in the antigen wells is \>0.78 IU/mL; this cutoff was determined based on the optimal sensitivity (85%) and specificity (100%) by a receiver operating characteristic (ROC) curve constructed from previous data \[[@pntd.0007216.ref019]\].

### Quantitative PCR (qPCR) {#sec014}

Parasite quantification by real-time polymerase chain reaction (qPCR) was carried out from buffy coat (isolated from blood collected in citrate tube) \[[@pntd.0007216.ref022]\]. Briefly, DNA was extracted using Qiagen DNA extraction kit and TaqMan based qPCR was performed using specific kDNA primes on each DNA sample in duplicateon an Applied Biosystem (ABI)7500 platform (22). For absolute quantification of parasite numbers in the samples, the standard curve method was performed as described previously \[[@pntd.0007216.ref022], [@pntd.0007216.ref023]\].

### SNP genotyping {#sec015}

SNP genotyping using a TaqMan based assay was performed as a surrogate method for the HLA-DRB1 screening of our study population at 2-digit level specificity. In our previous genome-wide association \[[@pntd.0007216.ref014]\] and follow-up imputation studies, we have shown that the rs9271255-G allele perfectly correlates with the HLA-DRB1\*01/\*15/\*16 allele groups which are associated with protection against VL. Here, we genotyped the HLA-DRB1-tagging SNP rs9271252 which is in perfect linkage disequilibrium with rs9271255 (r^2^ = 1 in Indian population), and can thus be used as a surrogate marker for determining the key risk versus protective HLA-DRB1 alleles. All the samples were genotyped on ABI 7500 real-time PCR platform using 20ng of purified gDNA per well. For SNP genotyping three levels were considered based on presence or absence of a protective HLA-DRB1 allele. Subjects could either be homozygous for non-protective alleles, heterozygous or homozygous for the protective alleles.

Quality control {#sec016}
---------------

As a quality control measure for each seroconverter identified both the original sample and the sample of the follow-up survey were rerun on the same plate for rK39 ELISA as well as for DAT. Subjects who were intially classified as seroconverters, but for whom quality control serologic testing disagreed with the initial baseline negative or follow-up survey positive results, were kept in the cohort but were reclassified as controls. The assessment of the association between seroconversion and disease was done comparing the final validated set of seroconverters to all controls, as well as by comparing the final set of seroconverters to only the original controls.

Data analysis {#sec017}
-------------

To determine the probability of progression to disease as a function of baseline status for various markers, we calculated odds ratios and confidence intervals using logistic regression. The factors on which converters and controls had been matched, i.e. village of residence and age group, were included in the models. Persons who developed VL before their inclusion in the cohort were excluded from the main analysis. For baseline DAT and rK39 results, we constructed Kaplan-Meier survival plots after subdividing both markers into three categories. DAT titers were regrouped on a 0 to 8 scale, each step representing an increase of one titer step from undiluted (0), via 1:400 (1) up to 1:25,600 or above (8). As cut off for being labeled DAT positive we chose a titer of 1:1600 or above based on our prior studies of subjects in this area \[[@pntd.0007216.ref012]\]. For further analysis we defined three categories, DAT negatives (titer \< 1:1,600), moderately DAT positives (titer ≥1:1,600 but \< 1:25,600) and strongly DAT positives (titer ≥ 1:25,600). For rK39 ELISA we used percentage points optical density. As we previously defined for subjects in the region, above 14 percentage points was considered positive. For further analysis we divided subjects into three categories based on percentage points (pp) optical density. Titers of ≤ 14 pp were considered negative, \>14 pp up to ≤40pp was considered moderately positive, above 40 pp as strongly positive.

Results {#sec018}
=======

Altogether 1,606 subjects were enrolled, including 476 seroconverters and 1,130 controls. Among the 1,130 controls, 79 were originally classified as seroconverters but re-classified after quality control. Altogether 978 subjects (61%) were female; the proportion was the same among converters and controls. The youngest subjects were two years of age; the oldest was 88 years. The median age of the group of seroconverters was 25 years as compared to 24 years for controls.

Over an average 52 months of follow-up, 17 persons developed VL, eight in the group of seroconverters and nine among controls, resulting in an odds ratio of 3.1 (95% CI 1.1--8.3). Most cases arose early during follow-up, with a median follow-up duration of 5 months and a maximum of 50 months. Fifteen out of 17 cases occurred in area 2, the area with the highest reported incidence at the time of the baseline survey. The association between seroconversion and progression to disease was only observed in this region (OR 3.5, 95% CI 1.2--9.8), whereas in Area 1 there was no association, the odds ratio was 1.3 (95% CI 0.08--21.1).

[Fig 1](#pntd.0007216.g001){ref-type="fig"} shows the probability of progressing to VL independent from the case/control group status. When analyzing all subjects together--seroconverters as well as non-seroconverters-there was a strong association between DAT at the start of follow-up and progression to disease. In the persons with high DAT antibody titers, 8 out of 77 subjects (10.4%) developed VL, all within nine months of follow-up, resulting in an odds ratio of 19.1 (95% CI 4.4--57.1) when compared to DAT negatives. In the latter category only 8 out of 1,175 (0.7%) developed VL.

![Risk of progressing to disease as a function of initial DAT titer.](pntd.0007216.g001){#pntd.0007216.g001}

For rK39 ELISA, findings were similar as for DAT. Out of 44 subjects belonging to the high titer category, seven (15.9%) developed VL, all within nine months, resulting in an odds ratio of 30.3 (95% CI 9.6--95.2) when compared to rK39 ELISA negatives ([Fig 2](#pntd.0007216.g002){ref-type="fig"}). In the latter category only 9 out of 1,416 (0.6%) developed VL.

![Risk of progressing to disease as a function of initial rK39 ELISA level.](pntd.0007216.g002){#pntd.0007216.g002}

Among 1,579 subjects tested with Quantiferon (IGRA assay) at the start of follow-up, 280 (17.7%) tested positive. Five out of sixteen VL cases occurred in this group, resulting in an odds ratio of 1.8 (95% CI 0.6--5.3).

Out of 1,604 subjects tested with qPCR, 68 were positive, i.e. exceeded the---1 parasite genomes/ml of blood. Out of those, six(8.8%) developed VL, compared to 11 out of 1,536 (0.7%) among qPCR negatives, resulting in an odds ratio of 20.9 (95% CI 6.5--66.8). All six progressed to disease within four months, four out of six even progressed within two weeks.

Of 957 subjects subjected to SNP genotyping, 380 (39.7%) were homozygous without the protective allele, 442 (46.2%) were heterozygous, and 135 (14.1%) were homozygous for the protective allele. With the first category (homozygous without the protective allele) as reference category, we found odds ratios of 0.61 (95% CI 0.2--1.8) and 0.62 (OR 0.13--3.1) respectively for the second and third category.

When looking at combinations of the three markers that were strongly associated with progression to disease, i.e. high DAT titers, high rK39 titers and qPCR positivity, we observed that relatively little gain in sensitivity was achieved by combining tests. Results are shown in [Table 1](#pntd.0007216.t001){ref-type="table"}. A high titer DAT identified 8 out of the 9 cases that were identified by combining the three markers.

10.1371/journal.pntd.0007216.t001

###### Numbers of subjects that tested positive at baseline to at least one test- at high cut-off, in several combinations of tests (n = 1,600) and numbers of VL cases that developed among those.

![](pntd.0007216.t001){#pntd.0007216.t001g}

  Category                                          Total positive in at least one of the tests(n = 1,600)   Incident VL cases among test positives (%)
  ------------------------------------------------- -------------------------------------------------------- --------------------------------------------
  qPCR positive and/or high DAT and/or high ELISA   142 (8.9%)                                               9 (6.3%)
  qPCR positive and/or high DAT                     133 (8.3%)                                               9 (6.8%)
  qPCRpositive and/or high ELISA                    103 (6.4%)                                               8 (7.8%)
  High DAT and/or highELISA                         86 (5.4%)                                                8 (9.3%)
  qPCR positive                                     68 (4.2%)                                                6 (8.8%)
  High DAT                                          77 (4.8%)                                                8 (10.4%)
  High ELISA                                        44 (2.8%)                                                7 (15.9%)

The strong overlap between baseline high DAT titers, high ELISA titers and qPCR positivity among incident VL cases is also apparent from [Table 2](#pntd.0007216.t002){ref-type="table"} below. This table also shows that for each of these markers VL cases among positives arose early during follow-up, an observation that was already visible in the Kaplan-Meier graphs. All cases among subjects that were not highly DAT and/or ELISA positive arose only after a minimum delay of six months. Among qPCR negatives the picture was similar though there was one exception of a case arising after just two months of follow-up.

10.1371/journal.pntd.0007216.t002

###### Delay between baseline screening and time of onset of disease for 17 VL casesin relation to their initial DAT, rK39 and qPCR status.

![](pntd.0007216.t002){#pntd.0007216.t002g}

  -----------------------------------------------------------------------------------
  ELISA titer   DAT titer   qPCR       Delay between baseline and appearance of VL\
                                       (months)
  ------------- ----------- ---------- ----------------------------------------------
  HIGH          HIGH        POSITIVE   1

  HIGH          HIGH        NEGATIVE   2

  HIGH          HIGH        POSITIVE   3

  HIGH          HIGH        POSITIVE   3

  HIGH          HIGH        POSITIVE   3

  HIGH          HIGH        POSITIVE   4

  NEGATIVE      NEGATIVE    NEGATIVE   6

  NEGATIVE      NEGATIVE    NEGATIVE   6

  MODERATE      HIGH        NEGATIVE   6

  NEGATIVE      MODERATE    POSITIVE   7

  NEGATIVE      NEGATIVE    NEGATIVE   8

  HIGH          HIGH        NEGATIVE   9

  NEGATIVE      NEGATIVE    NEGATIVE   18

  NEGATIVE      NEGATIVE    NEGATIVE   27

  NEGATIVE      NEGATIVE    NEGATIVE   32

  NEGATIVE      NEGATIVE    NEGATIVE   43

  NEGATIVE      NEGATIVE    NEGATIVE   51
  -----------------------------------------------------------------------------------

Discussion {#sec019}
==========

Our data show very strong associations between being qPCR positive at baseline and subsequent progression to VL (OR 20.8, 95% CI 6.5--66.8), the same applies to having a high DAT titer (OR 19.1, 95% CI 4.4--57.1) or a high rK39-ELISA titer (OR 30.3, 95% CI 9.6--85.2). There was only a moderately strong association between seroconversion and progression to disease, (OR 3.1, 95% CI 1.1--8.3). There was no significant association between progression to disease and positivity in the IGRA test (OR1.8, 95% CI 0.6--5.3). SNP/HLA genotyping showed a trend towards a protective effect of the genes tested, but the association was weak and non-significant. Both heterozygous and homozygous individuals for the protective variants had lower odds of disease when compared to individuals without the protective variants with odds ratios of 0.61 (95% CI 0.2--1.8) and 0.62 (OR 0.13--3.1) respectively.

This study corroborates our previous findings of a strong association between high DAT and rK39 titers and subsequent progression to disease, as well as the findings by Chapman and others in Bangladesh \[[@pntd.0007216.ref013], [@pntd.0007216.ref015]\].

The main strength of our study is that we followed up a cohort of seroconverters on DAT and rK39-ELISA over a relatively long period, three years, and included a number of other potential markers of infection. We also performed SNP/HLA genotyping. One of the major difficulties in studies of "asymptomatically infected" is that there is no clear consensus about the case definition. *L*.*donovani* infection status can be measured by antibody, antigen or nucleic acid detection or else by markers of cellular immunity in combination with a clinical assessment of signs and symptoms. Asymptomatically infected persons have been defined in various studies as those who show no clinical signs or symptoms of VL but are positive in at least one marker of infection such as the Leishmanin Skin Test (LST), a marker of cell-mediated immunity \[[@pntd.0007216.ref024]--[@pntd.0007216.ref026]\]; an antibody detection test as the DAT, rK39 ELISA, or IFAT \[[@pntd.0007216.ref005], [@pntd.0007216.ref006], [@pntd.0007216.ref012], [@pntd.0007216.ref027]\], or a molecular marker as qualitative or quantitative PCR to detect *Leishmania* spp. DNA \[[@pntd.0007216.ref005], [@pntd.0007216.ref028]--[@pntd.0007216.ref030]\]. Given the lack of agreement between these infection markers when measured cross-sectionally, the case definition of "asymptomatically infected" is a recurrent matter of discussion \[[@pntd.0007216.ref031]\].

Medley et al. \[[@pntd.0007216.ref011]\] pointed out how important early diagnosis of VL is, as it has an impact on individual prognosis as well as on curtailing transmission. Individuals with a high probability of developing clinical disease might be treated sooner if given an intense follow-up scheme. Based on our data it is, therefore, tempting to promote the high-titre DAT, high--titer rK39 ELISA, and qPCR as markers to identify persons at high risk for clinical VL. However, the relatively low positive predictive value of the markers (ranging from 8.8% for qPCR over 10.4% for high DAT titres and 15.9% for rK39) warrants a word of caution. As there is no easy and absolutely safe treatment available, an attitude of watchful waiting is probably best at this time, observing those persons closely to detect the first clinical signs early enough. If one decided to treat all the qPCR positives or all the high titre DAT positives, about nine out of ten persons treated would be treated without reason, while for the rK39 this amounts to 8 out of ten. Combining tests does not add much to sensitivity. It should also be noted that incident VL cases that were missed at baseline, i.e. that did not show high-titre rK39 and DAT, did not arise until 6 months after the start of follow-up; half of them arose only after 18 months of follow-up or later. These subjects may well have been infected during the follow-up period. Importantly, recent reports from Bangladesh indicate that incorporating rKR95 and rTR18 with rK39 in serological tests conferred a sensitivity of 84% and may enable simple and accurate detection of asymptomatic infection in surveillance \[[@pntd.0007216.ref032]\].

Finally, the potential epidemiological importance of the group of people with at least one positive marker of infection but no symptoms remains elusive. Are they all truly "infected"--i.e. latent carriers of *L*.*donovani*---with potential for transmission of the parasite or is this, more plausibly, a mixed group of i) very recently infected persons, ii) established latent carriers and iii). Immune persons who cleared their infection? It is hoped that the xenodiagnosis studies will shed some light on this question in the near future.

In conclusion, healthy persons living in VL endemic areas who have high antibody titers or test positive to qPCR have an increased probability to progress to VL disease. Such probability is not high enough to merit prophylactic treatment but carefull follow-up is warranted as most of those who do progress to disease eventually do so within the first 6 months.
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